Core Viewpoint - The company has received approval from the National Medical Products Administration of China for its self-developed product, Bo You Jing® (Aflibercept intravitreal injection solution), to treat adult neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) [1] Group 1: Product Overview - Bo You Jing® is a biosimilar to EYLEA®, with the active ingredient Aflibercept, which has a broader target action compared to anti-VEGF monoclonal antibodies, effectively inhibiting intraocular VEGF for a prolonged period [1][2] - The product has shown significant improvements in best-corrected visual acuity (BCVA) during clinical trials, demonstrating comparable efficacy and safety to the reference drug [2] Group 2: Market Potential - The market for anti-angiogenic eye drugs in China is projected to grow from RMB 1.27 billion in 2018 to RMB 4.99 billion by 2024, with a compound annual growth rate (CAGR) of 25.6% [3] - The prevalence of DME among diabetic patients is approximately 5.2%, while age-related macular degeneration (AMD) affects 20.2% of individuals over 70 years old in China, indicating a significant patient population for Bo You Jing® [2] Group 3: Strategic Partnerships - The company has partnered with leading ophthalmic pharmaceutical platform, OcuVist, to commercialize Bo You Jing® in mainland China, leveraging OcuVist's extensive commercial network and expertise [3] - The collaboration aims to enhance patient accessibility to the drug and reduce treatment burdens while creating new growth opportunities for the company [3]
博安生物：阿柏西普眼内注射溶液博优景®在中国获批上市